According to a recent LinkedIn post from Segmed, the company is highlighting a discussion around real-world deployment results of Brainomix 360 Stroke across 26 NHS hospitals. The post cites outcomes reported in The Lancet Digital Health, including a doubling of thrombectomy rates from 2.3% to 4.6% and a 64-minute reduction in door-in-door-out transfer times over a five-year evaluation of more than 450,000 patients.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post emphasizes that these figures reflect deployment outcomes rather than pure algorithm benchmarks, underscoring the operational and workflow dimensions of imaging AI adoption. Segmed is using its Bytes of Innovation forum to feature Brainomix’s Chief Medical and Innovation Officer, who is expected to discuss workflow redesign, network coordination, and trust-building with non-specialist centers as critical factors in scaling clinical AI.
For investors, the focus on practical implementation issues suggests Segmed is positioning itself at the intersection of AI technology and real-world hospital workflows, an area that can be a key bottleneck for commercial adoption. By curating discussions on moving tools “from cleared to clinically adopted,” the company may be seeking to strengthen its brand as a thought leader in healthcare AI quality and deployment, which could support long-term partnership opportunities and market relevance in the medical imaging ecosystem.